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Abstract: 
There  is  an  urgent  need  to  make  drug  discovery  cheaper  and  faster.   This  will  enable  the
development  of  treatments  for  diseases  currently  neglected  for  economic  reasons,  such  as
tropical and orphan diseases, and generally increase the supply of new drugs.  Here we report the
Robot Scientist “Eve” designed to make drug discovery more economical.   A Robot Scientist is
a  laboratory  automation  system  that  uses  artificial  intelligence  (AI)  techniques  to  discover
scientific knowledge through cycles of experimentation.  Eve integrates and automates library
screening,  hit  confirmation,  and  lead  generation  through  Quantitative  Structure  Activity
Relationship (QSAR) learning and testing.  Using econometric modelling we demonstrate that
the  use of  AI to  select  compounds  economically outperforms standard  drug screening.  For
further efficiency Eve utilizes a standardized form of assay to compute Boolean functions of
compound  properties. These  assays  can  be  quickly  and  cheaply  engineered  using  synthetic
biology, enabling more targets to be assayed for a given budget. Eve has repositioned several
drugs against specific targets in parasites that cause tropical diseases.  One validated discovery is
that the anti-cancer compound TNP-470 is a potent inhibitor of dihydrofolate reductase in the
malaria-causing parasite Plasmodium vivax.  
1. Introduction
New drugs are generally slow (> 10 years) and expensive (> $1 Billion) to discover and
develop.  Consequently tropical diseases, malaria, schistosomiasis, Chagas’ disease, etc., which
kill millions of people and infect hundreds of millions of others are “neglected” (Ioset & Chang,
2011; Leslie, 2011); and “orphan” diseases with few sufferers remain untreatable (Braum et al.,
2010).  More generally, the pharmaceutical industry is struggling to cope with spiraling drug
discovery and development costs (Pammolli et al., 2011).
The most important steps in early-stage drug design are shown in Fig. 1 (Gad, 2005).  A key
initial step is to develop an ‘assay’.  This is a ‘wet’ (biological/chemical) or ‘dry’ (computational)
experiment that estimates whether a small molecule (compound) is likely to treat a disease.  This
assay  should  be  relatively  cheap  and  fast  to  execute,  as  it  will  be  run  multiple  times.   A
compound that passes the assay is called a ‘hit’.  The next step is to run a drug screen, where a
“library”  (set)  of  compounds  is  tested  against  the  assay.   This  library  may  be  very  large,
tens/hundreds of thousands, maybe millions of compounds.  Such mass screening is generally
done in a brute-force and unintelligent way: ‘begin at the beginning and go on till you come to
the end: then stop’ (Lewis Carroll).  As the a priori probability of any library compound being a
hit is low, it is difficult to design an assay that does not have an appreciable number of false
positive hits.  Therefore, it is generally necessary to execute experiments to retest (‘confirm’) the
hits.  These experiments are more expensive and slow to execute, but have a far lower false
positive probability.   From the set  of confirmed hit activities a quantitative structure activity
relationship (QSAR) is learnt (Martin, 2010).  This is a function whose input is the structure of a
compound, and whose output is the predicted activity on the assay.  As the output is typically a
real number, QSAR learning is generally a regression task.  QSARs generalise the results of
assays and guide the synthesis of new compounds.  After new compounds are synthesised they
are tested against the hit confirmation assay, and the results of these assays are used to learn a
more accurate QSAR, and the cycle repeated.   The process is terminated when a compound is
found that that has a sufficiently high score on the assay, and passes other tests such as low
predicted toxicity, potential for modification, etc.  This compound is called a ‘lead’.
The  standard  way  to  improve  the  economics  of  a  process  is  through  automation  and
standardization (Bernal, 1969).  The use of automation has been enthusiastically pursued by the
pharmaceutical industry.  With much of this effort has gone into making library screening faster,
especially through miniaturisation,  with  the  result  that  high-throughput  robotic  systems now
routinely screen millions of compounds in library screens (Gad, 2005).  Less automation effort
has gone into the other steps of early stage drug design.  Standardization has been little used in
early stage drug design.  
A natural extension of the trend of increased involvement of automation in science is the
concept  of  a  Robot  Scientist  (King  et  al.,  2004;  King  et  al.,  2009).   A Robot  Scientist
automatically: originates hypotheses to explain observations, devises experiments to test these
hypotheses, physically runs the experiments using laboratory robotics, interprets the results to
change the probability of hypotheses, and then repeats the cycle.  In this way Robot Scientists
can automate high-throughput hypothesis led research.  Robot Scientists are also well suited to
recording scientific knowledge: as the experiments are conceived and executed automatically by
computer, it is possible to completely capture and digitally curate all aspects of the scientific
process. (King et al., 2009).  The first Robot Scientist ‘Adam’ was designed to plan and execute
yeast  microbiological  experiments.   Adam  was  fully  automated  and  there  is  no  essential
requirement  for  a  technician,  except  to  periodically add laboratory consumables and remove
waste.  Adam  was  the  first  machine  demonstrated  to  have  autonomously  discovered  novel
scientific  knowledge (King  et  al.,  2009).  Adam investigated  the  functional  genomics  of  S.
cerevisiae  and discovered the function of locally orphan enzymes – enzymes known to be in
yeast but for which the gene(s) encoding them are unknown (King et al., 2009).  The advances
that distinguished Adam from other complex laboratory systems (such as high-throughput drug-
screening pipelines, and X-ray crystallography crystal-screening systems) was its AI software, its
many  complex  internal  cycles,  and  its  ability  to  execute  individually  planned  cycles  of
experiments in high-throughput. 
In  this  paper  we  concentrate  on  finding  lead  compounds  for  neglected  tropical  diseases,
however we believe the methods used and conclusions are general.  The reasons for the focus on
neglected tropical diseases are:
 These disease are a scourge of humanity, infecting hundreds of millions of people, and
annually killing millions of people.
 The aetiology of these diseases is clear, as is what needs to be done to treat the disease
(kill the parasites), and how to achieve this treatment with a small molecule drug.  These
are not the case for many diseases targeted by the Pharmaceutical Industry.
 There is little competition from the much better funded Pharmaceutical Industry.
2. Eve
2.1 Design
We report the development of the Robot Scientist “Eve” designed to automate early-stage
drug design (Fig 2).  The initial design of Eve was given in (Sparkes et al. 2010).  Eve has three
integrated modes corresponding to  successive stages  in lead drug discovery.   In  its  Library-
screening mode Eve systematically tests each member from a large set “library” of compounds
against an assay in the standard brute-force way of conventional mass screening (Gad, 2005):
While simple to automate, brute-force mass screening is slow and wasteful of resources as every
compound in the library is tested.  It is also unintelligent, as it makes no use of what is learnt
during screening.  Eve starts the lead discovery process by mass-screening a subset of its library
to find “hit” compounds for the assay.  This subset was chosen randomly.
In its  Hit-confirmation mode Eve re-assays  the hit  compounds using multiple repeats and
titrations  to  reduce the probability of  false-positives.   Eve’s integration of screening and hit
confirmation  is  similar  to  advanced  screening  systems  that  first  execute  a  high-throughput
screen, and then a high-content screen for selected compounds.
Starting from the set of confirmed hits, Eve executes cycles of statistics/machine learning that
hypothesize QSARs, and tests these QSARs on new compounds.  As Eve currently does not have
access  to  chemical  synthesis  automation  (Baumann  et  al.,  2011),  we applied  Eve  to  screen
untested compounds from its library in lieu of synthesizing compounds.  Such intelligent library
screening may be more economical than standard mass screening as it potentially saves on time
and compound use.
2.2 Hardware
Eve’s robotic system is capable of moderately high-throughput compound screening: greater
than 10,000 compounds per day, depending on the length of time taken to assay compounds.
Eve is designed to be sufficiently flexible that it  can be rapidly re-configured to carry out a
number of different biological assays,  using fluorescence,  absorbance,  or cell  morphology as
read-outs (Fig. 2). Eve’s robotic system integrates a range of off-the-shelf pieces of laboratory
automation equipment into a single system that can perform library- screening, hit confirmation,
and  cycles  of  QSAR  hypothesis  formation  and  testing  using  selected  compounds  from  a
compound library. Eve can also be re-configured to copy compound libraries.
Eve’s  compound  library  is  maintained  in  a  dry-store,  with  the  compounds  dissolved  in
DMSO. Compounds to be assayed are transferred from the storage plates to the assay plates
using a non-contact acoustic transfer liquid-handling system. This has the advantages of high
accuracy and saving pipette  tips.  In  library-screening mode,  there  is  a  direct  mapping from
storage plates to assay plates, and a single transfer volume is used in each well.  In confirmation
and  intelligent-screening modes,  a  single  compound  from the  storage  plate  is  transferred  to
multiple  wells  in  the assay plate,  and at  different  volumes,  to  realize multiple  repeats  dose-
response experiments.  After the addition of assay compound, the target yeast strain pool is added
using a simple liquid-handling robot, as the same volume is added to each well.  The yeast pool
is created externally and stored by Eve for use.  Once the assay plates are formed they are placed
in  a  shaking incubator.   Every 90  minutes,  the  plates  are  removed  from the  incubator,  and
fluorescence measured.   Eve has two microplate  readers  capable of recording measurements
across a broad range of both excitation and emission wavelengths.  Eve also has an automated
microscope capable of taking both bright-field and fluorescence images across a broad range of
wavelengths.   Upon completion of the assay,  the plates  are  automatically removed from the
system.  To transfer the plates between different pieces of laboratory automation equipment, Eve
uses robotic arms and linear actuators.  All plates are bar-coded and movements recorded.
2.3. Low­level Software
Software was written to integrate Eve’s AI software with the robotics and thereby automate
and integrate Eve’s early-stage drug-design functions: library-screening, hit confirmation, and
QSAR cycles. The software to control the robotics, instrumentation, and used to execute the
experiments was written on top of PAA’s (PAA Peak Analysis and Automation Ltd, Farnborough,
UK)  Overlord  software.  An  interface  was  written  to  a  relational  database  that  stores  all
experiment-related data  and meta-data,  e.g.  all  fluorescence measurements.   The software to
parameterise growth curves for the different yeast strains in each well was taken from the Adam
project (King et al., 2009).  The main parameters are maximum growth, doubling-time, and lag-
time.  These growth parameters were then transferred to the AI QSAR software.  Software was
also  written  to  coordinate  library-screening,  and  to  plan  hit  confirmation.  This  was  also
integrated with the AI software so that the active learning could select compounds to test.
2.4. Automated QSAR Formation
To form QSARs Eve uses  least-squares linear  regression with mild 2-norm regularization
(ridge  regression).  This  can  be  interpreted  as  a  Gaussian  process  with  a  linear  kernel
(Rasmussen & Williams, 2006), hence we can compute the posterior uncertainty, allowing us to
use an optimization method which is more efficient, i.e. which needs fewer function evaluations
(De Grave et al., 2008).  The linear kernel choice has the distinct advantage that it permits more
efficient computation than other kernels when the feature space dimensionality is smaller than
the number of examples.  The feature space consists  of binary fingerprints of all  paths up to
length 7.  We computed these with Open Babel (O’Boyle, et al., 2011).
2.5. Active Learning
To select compounds to test its hypotheses Eve uses active learning (Cohen et al., 1996); De
Grave et al., 2008).  The active learning task is comparable to that in many other areas of science
and engineering: identify or design artifacts that have optimal performance.  However, it has an
extra ingredient reminiscent of reinforcement learning: balancing the exploration of compound
space with exploitation of regions of highly active compounds.  Another complication is that it is
desirable to identify the K best diverse compounds in the library: “leads” (De Grave et al., 2008).
Therefore, the QSAR active learning problem is: given a finite pool P of instances, an unknown
QSAR function f that maps instances x  P to their target values f(x), an assay (noisy “oracle”)
that can be queried for the target value of any x in batches of N, the number K of leads required;
then find the top K leads in P.  (In computer science an ‘oracle’ is a machine, the working of
which are unexplained, which always returns the correct answer to a question. A noisy oracle has
a  probability  of  returning  an  incorrect  answer.)   We  found  a  successful  approach  to  be  a
combination of selecting compounds with high estimated activity T, and high estimated variance,
i.e.  select  the  example  where  T+b√var (T )  is  maximal (De  Grave  et  al.,  2008)
(Supplementary  material).   As  it  is  generally  inefficient  to  assay  (or  synthesize)  a  single
compound in a QSAR cycle, batches of N compounds should be selected (for Eve, N=64).  Like
the requirement to find the K best leads this greatly increases the computational complexity of
choosing  the  best  experiment.   Therefore  Eve  adopts  a  greedy  strategy  to  select  batch
compounds.
3. Standardized Assays
There are three main forms of assay: computational (Lounkine et al., 2012), biochemical, and
cell-based (Vogel, 2002).  The most general type is computational (in silico screening, Schneider,
2010) - assuming the Church-Turing thesis (Deutsch, 1985), they could compute any conceivable
assay.  The advantages of in silico screening are that it is cheap, fast, and that compounds can be
tested without synthesizing them.  These enable very large libraries to be evaluated, and in silico
screening has proved its worth many time (Schneider, 2010).  The main disadvantage of in silico
screening is that it is still computationally infeasible to simulate the full complexity of biological
systems.  Biochemical assays have the advantage of being target-based (enabling rational drug
design),  but often assume a specific mechanism of interaction, and provide little information
about  toxicity,  drug uptake  into  cells,  and  in  vivo  activity.   Cell-based  assays  are  the  most
biologically realistic, but are rarely target based, and thus provide limited information on the
mechanism of action of a drug.  Moreover, cell-based assays are not applicable when searching
for compounds active against parasites that are not currently possible or difficult to culture (e.g.
Plasmodium  vivax).   All  these  types  of  assay  are  slow  and  expensive  to  develop  -  even
computational ones if reasonable realism is to be achieved.
We have  developed  a  standardized  form of  screening assay that  combines  advantages  of
computational  assays  (generality),  biochemical  assays  (targeted),  and  utilizing  live  cells
(biological realism, and early screening for toxicity) (Fig 3).  These assays  are designed to be
automatically engineered using existing laboratory automation, and can be generated much faster
and more cheaply than the bespoke assays that are currently standard.  This enables more types
of  assay to  be  executed,  more  efficient  use  of  screening facilities  to  be  made,  and  thereby
increases the probability of a discovery within a given budget.  The assays are biological systems
designed to compute Boolean functions of desired properties (Bememson  et al., 2004).  This
concept generalizes previous uses of engineered cells in drug discovery assays (Smith  et al.,
2010; Bilsland  et al., 2011; Bilsland  et al., 2013).  As an illustration, consider the example of
designing an assay that targets both wild type and drug-resistant DHFR against P. vivax (Figure
3).   To compute this function we first  engineer a chimeric yeast (Saccharomyces cerevisiae)
strain  with  its  DHFR coding sequence  (cds)  replaced by that  for  wild type  P.  vivax  DHFR
(yPvDHFRp),  then  engineer  a  second  chimeric  yeast  strain  (yPvRdhfrp)  with  its  DHFR  cds
replaced by that for drug-resistant P. vivax DHFR.  We then engineer a third chimeric yeast strain
(yHsDHFRp)  with its DHFR cds replaced by that for  H. sapiens  DHFR.  Finally, we apply the
biological  system to  assay  for  compounds  that  inhibit  growth  of  the  strains  expressing  the
parasite targets (yPvDHFRp and yPvRdhfrp) and not the strain expressing their human counterpart
(yHsDHFRp) (Chong & Sullivan, 2007).  Such compounds are ‘true’ for the assay.  They are
unlikely to be cytotoxic as one would expect all three strains to be inhibited.  (Of course this
does not completely remove the probability of human cytotoxicity as there could be off target
effects specific to human cells, therefore further studies may be required).  In practice Eve grows
the strains in competition mixed cultures in 384-well microtitre plates (Bilsland et al., 2013) in
the presence of one compound from its library.  The whole system is a model of what we really
are interested in: the in vivo survival of wild type/drug-resistant P. vivax cells versus those of its
human host. It can easily be seen that a set of genetically engineered yeast strains can compute
arbitrary complex Boolean functions of desired assay properties. 
4 Drug Screening and Repositioning
4.1. Standardised Assays
We first demonstrated that we could efficiently generate standardized assays.  We generated
assays  targeting  DHFRs  (wild  type  and  drug  resistant),  N-myristoyltransferase  (NMT),  and
phosphoglycerate  kinase  (PGK)  from  multiple  parasitic  organisms:,  Trypanosoma  brucei
(African sleeping sickness),  T. cruzi  (Chagas disease),  Leishmania major  (Leishmaniasis), and
Schistosoma mansoni  (Schistosomiasis) (Supplementary material).  These  assays  were  much
faster and cheaper to develop than using standard methods of assay development: engineering
each assay took about one person-month, and cost ~$15k.  A subset of these assays were reported
in Bilsland et al., 2013.  
4.2. Drug Screening
We then tested the utility of these assays, and the efficiency of Eve at standard screening, i.e.
running in its Library-screening and Hit-confirmation modes (Table 1).  We ran the Maybridge
Hitfinder library of approximately 14,400 chemically diverse compounds to these assays.  This
identified numerous hits.  A subset of these results were reported in Bilsland et al., 2013. 
4.3. Drug Screening for Drug Repositioning
We then applied the assays to the challenge of drug repositioning – the application of known
drugs to new diseases  (Table 1). To do this we again utilized Eve in its Library-screening and
Hit-confirmation modes to screen and confirm hits for the above assays, but using the  Johns
Hopkins University Clinical Compound Library that contains ~1,600 FDA-and foreign-approved
drugs.  Several repositioned compounds were found that discriminate between host and parasite,
and have passed initial cytotoxicity tests.  To maximize the utility and reuse of these screening
data they are available as open data in Resource Description Framework (RDF) format (Bizer et
al.,  2009)  at:  http://disc.brunel.ac.uk/eve-dataset/RDF_data_files.html  with  an  associated
ontology (Supplementary material). 
4.4. Repositioning TNP-470 as an Anti-malaria Compound
The compound TNP-470 was derived from the antimicrobial compound fumaglillin (Fig 4), it
is an angiogenesis inhibitor that has been investigated as an anti-cancer drug.  Its angiogenesis
activity is mediated by irreversible binding to and inactivating of methionine aminopeptidase-2
(MetAP2).  TNP-470 and its analogs have been shown to bind to P. falciparum MetAP2 in vitro,
to  inhibit growth of  P. falciparum  strains (including the chloroquine resistant strains W2 and
C2B), and to inhibit parasitemia in a mouse model (Zhang et al., 2002; Chen et al., 2009; Arico-
Muendel  et al., 2009).  Eve’s yeast synthetic biology assay results indicate that TNP-470  has
high activity against P. vivax  DHFR (Fig 5).  To further confirm that DHFR is an additional
target  of  TNP-470,  we  performed  DHFR enzyme inhibition  assays  (Leartsakulpanich  et  al.,
2002). We observed that P.vivax DHFR was 100-fold more sensitive to TNP-40 than its human
counterpart; the drug’s IC50 for the parasite enzyme being 0.16 µM, compared to > 165 µM for
human DHFR. This is consistent with the results of Eve’s assays, and suggests that our approach
identified a bona fide DHFR inhibitor with improved selectivity.
DHFR inhibitors are currently routinely used as prophylactics against malaria, and are given
to over a million children in seasonal malaria chemoprevention. However, DHFR inhibitors are
no  longer  used  as  a  standard  treatment  because  of  the  evolution  of  drug  resistance  (22).
Extensive efforts to discover a second-generation DHFR-targeted antimalarial drug with efficacy
against pyrimethamine-resistant strains have yet to produce a compound that has passed clinical
trials (Yuthavong et al. 2012).  Therefore, the discovery of an approved compound with activity
against DHFR is of high potential value.  It is also significant that TNP-470 is an example of
“polypharmacology”  (Besnard  et  al.,  2012),  in  that  it  targets  both  Plasmodium DHFR and
MetAP2.  This means that it should be pre-hardened to the evolution of drug resistance, as this
would require simultaneous alteration of both targets.
5. Automating Drug Development
5.1 Automating Drug Development
We  integrated  all  three  of  Eve’s  modes  together  to  demonstrate  that  early-stage  drug
development  can  be  automated,  including  QSAR  generate-and-test  cycles.   The  division  of
labour between Eve and the human scientists and technicians was as follows: the problem task
was first tightly defined by the humans by forming the assays, and defining the QSAR problem.
This was the extent of human intellectual effort.  Human manual effort was required to maintain
run Eve, maintain consumables, yeast stocks, etc.  Human manual effort was also required to run
certain programs during the different stages of the cycles, as some of the steps are not fully
integrated; these program steps are predetermined, and could if necessary be fully automated.
The first full experimental tests of the active learning loop were conducted by splitting the
screen data set for TS6 (comprising the heterologous DHFR yeast strains for P. falciparum, P.
vivax, and that of humans) using 4,800 compounds as a training set. The ratio of the yields of the
HsDHFR and PvDHFR strains were passed to the selection algorithm, together with fingerprints
of the remaining 9600 compounds. The results from the first ‘cherry-picking’ round (compounds
selected  by  active  learning  and  using  the  hit  confirmation  assays)  (n=96;  12  plates  of  8
compounds per plate; 8 replicates of 6 concentrations) were then added to the original data set,
and  a  second  cherry-picking  round  conducted.   We  used  this  data  to  evaluate  different
approaches to the problem of combining cherry-picking and mass screening data.  The approach
based on using the mean of replicates multiplied by log(10/conc.) was found to perform best.  We
then ran active learning loop was run through three iterations; an initial set of 4,800 compounds
was  screened  (single  iteration,  10  μM),  and  three  loops  of  96  cherry-picked  compounds  (8
replicates, at a range of concentrations) were selected. The mean log-weighted cherry-picking
data is cycled back into the training set.
5.2. Econometric modelling
A thorough  investigation  of  Eve’s  QSAR active  learning  methods,  comparing  intelligent
screening  versus  standard  brute-force  screening,  would  require  the  analysis  of  thousands  of
cycles.   We  therefore  decided  to  utilize  our  empirical  results  from  using  Eve  (in  Library
screening mode) against  the complete  set  of 14,400 compounds of the  Maybridge HitFinder
library against  dihydrofolate reductase (DHFR) assays from multiple parasitic organisms (see
above) - we considered the Johns Hopkin’s library to be too small for intelligent screening.  The
idea is to use these results as an oracle - instead of new physical experiments.  
To quantify the utility of intelligent screening we developed an econometric model (Figure 6).
In this model the net utility is the cost saving due to not screening compounds, minus the cost
due to  missing any hits,  minus the cumulative cost  of the number of  active learning cycles
performed.  Active learning was applied to the seed input data, and predictions made to produce
simulated learning curves.  The progression of these learning curves was then compared to the
base case of standard library screening.  For each 96-compound loop the utility equation was
applied.   Fig.  7  shows  the  result  of  one  such  run  involving  many cycles  of  learning,  and
demonstrates hit enrichment by intelligent screening.  
We used the model to investigate a range of costings to determine under what conditions it is
economically advantageous compared with performing a standard whole-library screen.  Fig. 8
shows that under most conditions it is economically rational to screen intelligently.  Assuming
that the probability of a compound being a hit is independent of the size of the library i.e. they
are independent and identically distributed variables (iid), then the utility gained from intelligent
screening is proportional to the size of the library - larger libraries produce larger savings.  The
iid assumption is reasonable and, in large part, the motivation for the collation of the very large
libraries currently used for screening.  However it  is  also conservative,  as the difficulties in
physically creating libraries means that the probability of an individual compound being a novel
structural hit probably decreases with the size of the library, which means that the savings are
probably much greater for large libraries.  Therefore intelligent screening is more cost-effective
with larger libraries, more valuable compounds, and fast cycles of assay screening and testing -
this is the standard regime for pharmaceutical screening, suggesting that adoption of intelligent
screening is economically rational.  
6. Data and Code
To facilitate the confirmation and reuse of Eve’s screening assay results we have made this
openly available as linked open data (LOD) in Resource Frame Framework (RDF) format (Bizer
et  al.,  2009).  A semantic  data  model  of  Eve’s  screening  assay  results  was  developed  (see
Supplementary Information). The root node “assay triple screen” represents the main group of
data items used to analyse the results.  This root node is linked to the node “Eve” via the relation
ro:has-agent.  The semantics of this association are that Eve initiates and runs the process “assay
triple screen”.  The assay triple screen process has the following inputs (ro: has-input): synthetic
yeast  strain(s),  each  has  a  unique  identifier  and  ro:has-part fluorophore  and  DHFR target;
compound is represented by SMILES code and sio:has-identifier compound common name and
Maybridge hit finder ID; plate is represented by a code and ro:has-part well-column and well-
row to identify each well.  The semantics of these associations are that synthetic yeast strains,
compounds,  and a  plate  participate  in  the assay triple  screen  process  and are  present  at  the
beginning of the process. The assay triple screen process has the following outputs (ro: has-
output): venus, sapphire and cherry initial fluorescence in a well; venus, sapphire and cherry
final fluorescence in a well; venus, sapphire and cherry doubling time in a well; venus, sapphire
and cherry lagtime2 in a well; venus, sapphire and cherry error code in a well.  The semantics of
these associations are that initial and final fluorescence, doubling time, lagtime2, and error code
measurements were produced by the assay process and are present at the end of the process.
Additionally, the relation has-target-origin was introduced to link a target and an organism of
origin. We included this relation and other entities that are required to define semantic meaning
of Eve data in a small ontology EVE that was specially designed to support the semantic data
model of Eve’s screening assay results (http://disc.brunel.ac.uk/eve.). The node “DHFR target” is
linked via this relation to the host (Homo sapiens) and parasites.  A target may be drug resistant.
This is expressed via the link sio:has-quality. Currently the dataset is deposited at the closed site
http://disc.brunel.ac.uk/eve-dataset.  On  publication  Eve  dataset  will  be  deposited  as  LOD
(Linked Open Data) (Bizer et al., 2009) at the open site Bio2RDF http://bio2rdf.org/eve.
To facilitate  the reuse of the code we have placed all  the low-level  software,  and QSAR
software used on Github using the GNU General Public License version 3.   
6. Discussion and Conclusion
Eve’s standardized assays could easily be engineered for other targets/species (e.g. bacteria),
or indirect targets (e.g. to drug import or efflux pumps), or more complicated functions (e.g. to
screen  for  drug synergies  across  multiple  targets).   In  addition the  biological  realism of  the
assays could be increased by the incorporation of many more human/parasite genes.   The assays
could also be modified to be much faster - as using growth as the read-out limits the speed of
executing the assay.
The economics of drug development are clearly influenced by many factors (Ioset & Chang,
2011; Leslie, 2011;  Braum  et al., 2010; Pammolli  et al., 2011) some technical (understanding
how to intervene to  treat  a disease,  the difficulty of  achieving the intervention,  etc.),  others
societal  (safety standards, the price of drug, etc.).   Although the costs of drug discovery are
substantial, they are relatively small compared to later stages in development.  Such arguments
tell against increased automation and standardization in drug discovery making much economic
difference.  However, they fail to take into account the “art of the soluble” (Sir. Peter Medawar).
Preventing  drug  failures  in  late-stage  development  is  an  intrinsically  very hard  problem,  as
human biology is very complex.  In contrast,  we argue that a radical decrease in the cost and
increase  in  the  speed  of  drug  discovery  could  be  achieved  by  the  full  automation  and
standardization of procedures.  By this we mean a robotic system that once given a target could
autonomously develop a standardized assay for that target, screen a compound library using that
assay,  confirm  hit  compounds,  and  identify  lead  compounds  through  cycles  of  quantitative
structure activity relationship (QSAR) learning and testing.  This could be achieved today: Eve’s
synthetic biology assays could be automated using existing technology, and chemical synthesis
machines exist that could be integrated with Eve (Baumann et al., 2011).  Such integration would
achieve  the  goal  of  a  robotic  system that  could  autonomously generate  hits  for  targets,  and
radically decrease the cost and increase the speed of drug discovery.
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Disease Species Enzyme Drug 
resistant
Libraries
malaria P. falciparum DHFR no May
malaria P. falciparum DHFR yes May
malaria P. falciparum DHFR no May
malaria P. vivax DHFR no May
malaria P. vivax DHFR yes May
malaria P. vivax DHFR no May
malaria P. vivax PGK no May
malaria P. vivax NMT no May
Chagas T. cruzi DHFR no May
Chagas T. cruzi PGK no May
Chagas T. cruzi NMT no May
African sleeping sickness T. bruci DHFR no May
African sleeping sickness T. bruci PGK no May
African sleeping sickness T. bruci NMT no May
schistosomiasis S. mansoni DHFR no May
schistosomiasis S. mansoni PGK no May
schistosomiasis S. mansoni NMT no May
leishmaniasis L. major DHFR no May
bacterial infection S. aureus DHFR no May
Table 1.  The targets (disease/ species/ protein/ drug-resistant) and libraries screened (May = 
Maybridge Hitfinder, JH –Johns Hopkins University Clinical Compound Library)
Figure Legends
Figure 1. Early-stage Drug Design.  The contribution of standardized synthetic biology assays
and Eve to a cheaper faster drug discovery pipeline.
Figure 2a.  A diagram of Eve.  Showing the location of the main instruments.
Figure 2b.  A photo of Eve.  Eve has been designed to be flexible in terms of the biological
assays that it can perform, and is physically capable of screening at a moderately high throughput
rate.
Figure 3. The form of the standardized assays. From biological knowledge a specific objective
is determined; this is compiled into a propositional logic function, and synthetic biology is used
to engineer a set of yeast strains that compute the function. 
 
Figure 4.  The structure of TNP-470
Figure 5.  An Eve hit confirmation run with four replicates. TNP-470 dose response curves
for: yHsDHFRp (red), yPfDHFRp (green), and yPvDHFRp (blue).  Normalized growth is calculated
by comparison to in-plate negative controls.
Figure  6.  Modelling  the  economics  of  drug  discovery.   The  econometric  model  of  the
differential utility of intelligent screening versus mass screening with hit confirmation. 
Figure 7.  Intelligent v Random Screening. An example simulation run of intelligent screening:
cycles of QSAR learning/testing from a compound library.  The data are taken for a screen of the
Maybridge  Hitfinder  library  against  the  P.  vivax  DHFR as  target  (Supplementary  material).
Intelligent screening is red, and standard brute-force black. The differential utility of intelligent
screening is shown in blue, and the dotted line indicates its maximum. It can be seen that it is
cost-optimal to screen between a third and a half of Eve’s small library, with a larger library the
screened proportion would be expected to be smaller.  Similar diagrams for the other targets can
be found in the Supplementary material. 
Figure 8.   Summary of  Utility  Modelling.   Diagram of the maximum utility of  intelligent
screening taken from a systematic scan of different costs/utilities in the econometric model (A),
using the screening results in (B). To make these results comprehensible, we project them down
into a  3-dimensional  graph and combine cost/utilities:  Time-ratio = Tc/Tm, and Cost-ratio =
Uh/Cc.   This  indicates  that  intelligent  screening  is  generally  rational  (there  is  little  area  of
negative utility), and that a high time-ratio (fast screening) and low cost-ratio (valuable library
compounds) are most favorable.
